OspA protein

Subscribe to Selected New Research on OspA protein

138 relevant articles (11 outcomes, 13 trials/studies) found for this Bio-Agent

Description: amino acid sequence given in Gene 1992;120(1):127-8; MW 31 kD; a promising candidate for a human Lyme disease vaccine; LYMErix is a Lyme disease vaccine, shown to be effective and safe in preventing Lyme disease in adults and adolescents

Also Known As:

Borrelia burgdorferi outer surface protein A; LYMErix; OspA vaccine; ospA protein, Borrelia burgdorferi; outer surface protein A

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Van Hoecke, C: 2 articles (07/2001 - 03/2000)
2.	Sikand, V K: 2 articles (07/2001 - 03/2000)
3.	Buscarino, C: 2 articles (07/2001 - 03/2000)
4.	Parenti, D L: 2 articles (12/2000 - 03/2000)
5.	Nardelli, Dean T: 1 article (07/2008)
6.	Kevin Luk, Kee Hang: 1 article (07/2008)
7.	Torrealba, Jose R: 1 article (07/2008)
8.	Warner, Thomas F: 1 article (07/2008)
9.	Schell, Ronald F: 1 article (07/2008)
10.	Kotloski, Nicholas J: 1 article (07/2008)

Related Diseases

1.	Lyme Disease (Disease, Lyme) 06/01/1995 - "In vivo vaccination studies supported the in vitro findings, confirming that vaccination with a single OspA protein does not provide complete protection against challenge with all Lyme disease spirochetes. " 07/01/1998 - "Compared with placebo, the OspA vaccine significantly reduced the frequency of Lyme disease during the 2-year study period (P < 0.04, one-tailed Fisher's exact test). " 07/23/1998 - "CONCLUSIONS: In this study, OspA vaccine was safe and effective in the prevention of Lyme disease." 01/01/2003 - "BACKGROUND: An efficacy trial of an outer-surface protein A (OspA) Lyme disease vaccine demonstrated tolerability and efficacy against laboratory-confirmed Lyme disease after a primary series of 3 doses at 0, 1, and 12 months.OBJECTIVES: This extension of the efficacy study assessed the immunogenicity and tolerability of booster vaccinations administered at 24 and/or 36 months after the first vaccination. " 07/23/1998 - "We assessed the efficacy of a recombinant vaccine consisting of outer-surface protein A (OspA) without adjuvant in subjects at risk for Lyme disease. " Order ALL the reference details at left...
2.	Infection 03/01/1997 - "Data presented here demonstrate a significant correlation between antibody to an epitope on outer surface protein A (OspA) and protection against infection with Borrelia burgdorferi in canines and mice. " 05/01/2006 - "In this study, 746 questing Ixodes (I.) ricinus ticks from eastern Slovakia and 187 ticks from southern Poland were investigated for infection with Borrelia (B.) burgdorferi sensu lato and different outer surface protein A (OspA) types by an improved restriction fragment length polymorphism (RFLP) analysis of the ospA gene. " 01/01/2007 - "In 1998, the FDA approved a new recombinant Lyme vaccine, LYMErix, which reduced new infections in vaccinated adults by nearly 80%. " 09/01/2005 - "burgdorferi in PEG-IC preparations is not more likely to reflect active infection than testing in unprocessed serum and should not be used in individuals who received the OspA vaccine." 06/24/2003 - "The primary laboratory outcome was an experimental measure of CSF infection, outer surface protein A (OspA). " Order ALL the reference details at left...
3.	Bites and Stings (Sting) 10/01/1997 - "Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii." 06/01/2005 - "A recombinant outer surface protein A (OspA) vaccine was approximately 80% effective in clinical trials in the United States, and a single 200 mg dose of doxycycline given within 72 hours of an I. scapularis tick bite, was shown to be 87% effective. " Order ALL the reference details at left...
4.	Arthritis (Polyarthritis) 08/01/2007 - "Molecular mimicry between OspA (outer surface protein A) and adhesion molecule LFA-1alpha seems to be responsible for chronic arthritis." 04/15/2001 - "A marked Ab and T cell response to BB: outer surface protein A (OspA) often develops during prolonged episodes of arthritis. " 12/01/2000 - "Outer surface protein A and arthritis in hamsters." 02/01/2000 - "Here we provide direct evidence that a major surface protein, outer surface protein A (OspA), can induce arthritis. " 04/01/1996 - "In an earlier study, we found that T-cell lines (TCL) from five patients with treatment-resistant Lyme arthritis preferentially recognized Borrelia burgdorferi outer surface protein A (OspA), but TCL from four patients with treatment-responsive arthritis only rarely recognized this protein. " Order ALL the reference details at left...
5.	Erythema 10/01/2001 - "Our analysis of the asymptomatic infections diagnosed serologically in a recent OspA vaccine trial conducted in the United States (N Engl J Med 1998;339: 209-215), suggests that the natural history of this event is more benign than that reported for untreated patients with erythema migrans (Ann Intern Med 1987;107: 725-731). " 08/01/1996 - "Spirochete diversity in acrodermatitis chronica atrophicans lesions in a closely defined central European site was compared to that in the local vector population, in human erythema migrans lesions, and in cerebrospinal fluid by amplifying and sequencing a segment of the gene of outer surface protein A directly from sampled tissues. " 03/01/1998 - "The eight isolates obtained from the ticks and one skin isolate from a Bulgarian patient with erythema migrans were subjected to phenotypic [outer surface protein A (OspA) serotyping] and genotypic analysis (pulsed-field gel electrophoresis typing followed by large restriction fragment pattern analysis after MluI digestion, polymerase chain reaction with 16S rRNA-directed oligonucleotide probes, and restriction fragment length polymorphism analysis of rrf-rrl intergenic spacer amplicons). " 02/01/1994 - "Only 1 patient each with erythema migrans, arthritis, or acrodermatitis had weak reactivity with outer surface protein A (OspA), and none responded to OspB. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	OspA protein
2.	Lipoproteins (Lipoprotein)
3.	Doxycycline (Vibramycin)
4.	Aluminum
5.	Antibodies
6.	Antigens
7.	Vaccines
8.	Peptides
9.	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
10.	HLA-DR Antigens (HLA-DR)

Related Therapies and Procedures

1.	Injections
2.	Intraperitoneal Injections

Best Treatments:
Research Summary Report
on Lyme Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 99 Outcomes
Top 200 Key Drugs and Biologics
Top 31 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>